Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Enveric Biosciences对第四季度和全年业绩持乐观态度：“受迷幻启发” 的未来增长药物
Nasdaq-listed psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) shared its financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023, results showing:
在纳斯达克上市的迷幻药生物技术公司Enveric Biosciences（纳斯达克股票代码：ENVB）分享了其2023年第四季度和截至2023年12月31日的财年的财务业绩，业绩显示：
Cash in hand of $2,287,977 by December 31, 2023, as compared to the $17,723,884 held by December 31, 2022.
Yearly R&D expenses of $7.3 million, vs. the $8 million spent in 2022.
Yearly general administrative (G&A) expenses of $8.9 million, vs. the $11.6 million spent in 2022.
Total yearly operating expenses of $16.4 million, vs. the $27.4 million spent in 2022.
Yearly net cash used in operations totaled $14.1 million, vs. $17.1 million in 2022.
Quarterly net loss of $3.44 million (or $1.46 loss per share), vs. a net loss of...
截至2023年12月31日，手头现金为2,287,977美元，而截至2022年12月31日持有的现金为17,723,884美元。
每年的研发费用为7...
登录免费看全文
登录/注册